This Stock Just Broke Out on a Major FDA Approval – Could Soar 22%–35%

We flagged Vera Therapeutics, Inc. (NASDAQ: VERA) in our watchlist this past Sunday — and the stock has since broken out powerfully and looks headed even higher.

As we’ll get to just ahead, the combination of a major regulatory breakthrough, a fast-tracked path to full approval that puts it years ahead of schedule, and a fresh technical breakout makes VERA one of the more interesting setups on the board. Here’s what’s going on…

The Themes Behind the Move

Vera Therapeutics is a U.S.-based biotech focused on developing and commercializing treatments for immunological diseases, with its lead therapy targeting a serious kidney condition called IgA nephropathy (IgAN) — a disorder in which the immune system damages the kidneys’ filtering units and, left unchecked, is a leading cause of kidney failure.

In plain English, Vera’s flagship drug is a once-weekly at-home injection that switches off two of the key immune signals driving that kidney damage. Until this week, Vera was a clinical-stage company still waiting on regulators; that changed overnight. Its business now hinges on how quickly it can launch that drug commercially, how the confirmatory kidney-function data reads out later this year, and how it stacks up against a fast-growing field of competitors chasing the same market.

VERA’s latest move reflects a powerful confluence of developments — regulatory, clinical, and commercial — that have come together in rapid succession to fundamentally reframe the company’s near-term growth trajectory.

If needed, swipe or scroll sideways to view the full table.

Put it all together, and VERA is looking less like a speculative pre-approval biotech leaning on trial hopes and more like a freshly de-risked, commercial-stage franchise with an approved first-in-class drug, an FDA-blessed fast track to full approval, a deep cash runway, and a field of deep-pocketed acquirers circling the space.

The story is getting stronger by the week, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Downtrend Channel Breakout: VERA spent the last several weeks compressing inside a well-defined descending channel (marked in purple on the daily chart). That structure is now broken. Price pushed through the upper rail with conviction, pulled back cleanly to retest the breakout level, and is turning higher off that retest — the textbook sequence that separates a durable breakout from a false one. A descending channel gives way only when buyers have absorbed every layer of overhead supply the channel was feeding them and are still bidding higher. The successful backtest is the confirmation: former resistance is now acting as support. This reframes the prior decline as a corrective phase inside a larger uptrend, not the opening leg of a sustained move lower.

VERA – Daily Chart

#2 Price above MAs: VERA is trading above both the 50-day and 200-day SMAs, placing it firmly in bullish territory on the daily timeframe. More telling is how the two averages sit: tightly clustered just beneath price, with the 50-day ($36.25) closing in on the 200-day ($38.11) from below. That compression is what a market looks like after it has finished digesting overhead supply and is coiling for a directional resolution — and with price already above both, the resolution is tilting up. The clustered MAs also give buyers a defined, layered support zone to lean on if the stock pulls back.

#3 MACD Above Signal Line: On the daily, the MACD line (light blue) has crossed above its signal line (orange) and both are lifting off the zero line together — a bullish crossover with the added weight of coming from a compressed base rather than an extended one. The read is straightforward: short-term momentum is accelerating faster than longer-term momentum, meaning buying pressure is not just present but expanding. Crossovers that fire from a flat base tend to have more runway than those that fire when the indicator is already stretched, which is what makes this particular signal worth acting on rather than fading.

#4 Bullish ADX: The ADX read here is textbook early-trend, and two things stand out. First, +DI has crossed decisively above –DI, locating directional pressure firmly on the buy side. Second — and the more important read — ADX itself is inflecting higher from a compressed base beneath both DI lines. Because ADX is direction-agnostic and measures only trend strength, a rise from a low reading is the indicator’s way of saying a new trend isn’t just forming, it’s gathering force. The fact that ADX is still climbing rather than curling over matters: a flattening ADX at these levels would read as exhaustion; a rising one reads as runway. Stacked against the channel breakout and MACD crossover, all three momentum reads are pointing the same direction — and that alignment is what elevates this from a single signal to a confluence.

#5 Cup and Handle Pattern Breakout: Zooming out to the weekly, VERA has broken out of a cup and handle — one of the most reliable long-term continuation patterns in technical analysis. The rounded “U” of the cup reflects an orderly, months-long absorption of selling pressure; the shallow drift lower that formed the handle acted as a final shakeout of weak hands before the move higher. The breakout above handle resistance is the confirmation that institutional participation has stepped in, and the pattern’s depth and duration point to the potential for a sustained, multi-week advance rather than a short-lived pop. Reinforcing the setup, price is trading well above both the 50-week ($36.11) and 200-week ($27.81) SMAs, confirming the higher-timeframe trend structure is aligned with the breakout.

VERA – Weekly Chart

#6 %K above %D: On the weekly, %K has crossed above %D and is rising out of the mid-range — a signal that buying momentum is overtaking selling pressure on a longer-term basis. Two things give this crossover added weight. First, the timeframe: weekly stochastic signals filter out the intraweek noise that muddies daily reads, so a crossover here reflects a genuine shift in momentum rather than a short-lived swing. Second, the location: the cross is firing from the middle of the range rather than from overbought territory, meaning there’s room for the signal to develop before any exhaustion risk enters the picture.

#7 Bullish RSI: The weekly RSI has cleared 50 and continues to trend higher — a two-part confirmation that carries more weight than either read alone. Crossing 50 signals that buyers now hold the momentum advantage over sellers on the higher timeframe; the continued upward trajectory tells us that advantage is expanding, not plateauing. An RSI simply sitting at 50 is a coin flip; an RSI that has crossed 50 and is still climbing is a directional statement. Combined with the cup-and-handle breakout and the weekly stochastic cross, the higher-timeframe momentum picture is unambiguously constructive.

Risks to Consider

Even strong setups can fail, especially in a volatile clinical-stage-turned-commercial biotech like Vera. A few things could knock the stock off course:

• A breakdown back below the trend-channel breakout level on heavy volume would invalidate the bullish technical thesis
• Negative company-specific news, broader market weakness, or a sector rotation out of biotech would pressure the entire IgAN group
• Confirmatory data risk — the accelerated approval hinges on positive Q3 2026 eGFR kidney-function data to support full approval and label expansion; a disappointing readout would be a major setback
• Commercial execution risk — going from the lab to selling a drug is hard; Vera must build out a sales force and secure insurance coverage with a brand-new launch team and high post-rally expectations
• Insider selling — in late June 2026, CEO Marshall Fordyce sold roughly $701,000 of stock (18,500 shares); this was a scheduled 10b5-1 plan and a fraction of his holdings, and institutions loaded up over $200 million in VERA earlier this spring, but the activity is a sentiment item to watch
• Profitability timeline — Vera is pre-revenue until commercial launch, and continued heavy spend on the launch could widen losses before revenue scales
• Competition — the IgAN space is crowded, with Otsuka, Vertex’s povetacicept (strong Phase 3 data), and Novartis (whose sibeprenlimab posted a slightly higher 51.2% protein reduction in separate trials) all vying for share
• Regulatory or sector-level risk — any shift in FDA posture, reimbursement, or the broader biotech tape could weigh on the stock regardless of company-specific execution

The Bottom Line

VERA is breaking out of a multi-week descending channel on the daily chart while also clearing a long-term cup-and-handle pattern on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.

The fundamental story underneath the chart is just as strong: a first-in-class FDA accelerated approval for its lead drug, an FDA-blessed fast track that pulls full approval years forward, and a deep ~$597M cash runway funding operations into 2027.

Combine that with multiple commercial and clinical catalysts staggered through the back half of 2026 and into 2027 — Q2 earnings in August, the confirmatory Q3 eGFR readout, the mid-2026 commercial launch, monthly-formulation data, and the planned Q4 sBLA filing — and VERA looks like one of the more compelling risk-reward setups on the board right now.

If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our exact entry level, both price targets that imply 22%–35% potential upside, and the stop-loss we’re using to manage the downside.

Recommended Trade Setup

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $4.90 per share, the target rewards are about $9.60 and $15.60 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If VERA drops to or below the $39.50 stop-loss before the $44.40 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.

Happy Trading!
Tara and Greg